EKF Diagnostics Holdings PLC Notice of Results (9105E)

TIDMEKF

RNS Number : 9105E

EKF Diagnostics Holdings PLC

04 March 2020

EKF Diagnostics Holdings plc

("EKF", the "Company")

Notice of Results

Investor results briefing

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.

Investor briefing

A briefing open to all investors will take place on Tuesday 24 March 2020 at No.1 Cornhill, London, EC3V 3ND from 4.30pm for a 4.45pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email ekf@walbrookpr.com

 
     EKF Diagnostics Holdings plc                                         www.ekfdiagnostics.com 
     Christopher Mills, Non-Executive Chairman                                Tel: 029 2071 0570 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
 
     N+1 Singer (Nomad & Broker)                                              Tel: 020 7496 3000 
     Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate 
      Finance) 
      Tom Salvesen (Corporate Broking) 
 
     Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com 
     Paul McManus/ Lianne Cawthorne                                   Mob: 07980 541 893 / 07584 
                                                                                         391 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORFZGGFNFGGGZM

(END) Dow Jones Newswires

March 04, 2020 02:00 ET (07:00 GMT)

EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
From Jun 2024 to Jul 2024